PolyPeptide Group AG shareholders approved all board proposals at an extraordinary general meeting, electing a new board and removing governance barriers that had stood in the way of a public tender offer by Samsung Peptide AG, a wholly owned subsidiary of Samsung Biologics Co., Ltd. The approvals are subject to and effective upon settlement of the offer, marking a decisive step toward the company's acquisition.
Shareholders elected John Chongbo Rim, Seungho Ryu, Cheol Woo Ryu, Mihyun Yang and Joonkyung Seong as board members for terms ending at the next annual general meeting. Rim was elected chair, while Cheol Woo Ryu and Seungho Ryu were appointed to the Remuneration and Nomination Committee. The new leadership will take office only once the tender offer settles, ensuring continuity during the transaction.
The meeting also resolved to remove transfer restrictions and voting limitations from PolyPeptide's articles of association, conditional on the satisfaction or waiver of all offer conditions in Samsung Peptide AG's 31 August 2026 offer prospectus, except for one specified condition. This change eliminates structural defenses that could have impeded Samsung's acquisition of all publicly held registered shares.
The implications are significant for PolyPeptide, a specialized contract development and manufacturing organization for peptide-based active pharmaceutical ingredients. As a global CDMO with six GMP-certified facilities across Europe, the U.S. and India, PolyPeptide serves a fast-growing market with substantial exposure to metabolic diseases, including GLP-1 therapies. The board overhaul and removal of transfer restrictions effectively align the company's governance with the impending ownership structure, reducing uncertainty for customers and investors.
For Samsung Biologics, the approvals clear a critical path to full ownership, potentially strengthening its position in the peptide manufacturing sector. The transaction's completion depends on the remaining offer conditions, but the shareholders' decisive backing signals strong support for the deal. As the company notes, its broad portfolio reflects opportunities across drug therapies, and the new board's mandate will begin at a pivotal moment for the business.
Investors and industry observers will now focus on the settlement of the tender offer and the integration of PolyPeptide into Samsung Biologics. The original release is available on NEWMEDIAWIRE, and further details about PolyPeptide can be found at polypeptide.com. The company also maintains a presence on LinkedIn.
